A synthetic “cocktail” vaccine SPf66 has shown potential for the protection against
**Question:** A synthetic "cocktail" vaccine SPf66 has shown potential for protection against which infectious disease?
**Core Concept:** Synthetic "cocktail" vaccines are combinations of multiple antigens derived from a single pathogen, aiming to stimulate a robust immune response. SPf66 is a synthetic vaccine derived from Plasmodium falciparum, the causative agent of malaria.
**Why the Correct Answer is Right:** SPf66 is a multi-antigenic vaccine composed of six proteins (PF1, PF3, PF4, PF5, PF6, and PF7) from Plasmodium falciparum, the parasite responsible for causing malaria. This multi-antigenic approach increases the chances of inducing a strong and long-lasting immune response, potentially leading to increased protection against malaria infection.
**Why Each Wrong Option is Incorrect:**
A. Malaria: SPf66 targets P. falciparum, not P. vivax or P. ovale, which are also responsible for malaria infections.
B. Typhoid: SPf66 is specific to P. falciparum and does not protect against Salmonella typhi, the causative agent of typhoid fever.
C. Hepatitis B: SPf66 is a vaccine against malaria, not hepatitis B, caused by the hepatitis B virus.
D. Dengue: SPf66 is specific to P. falciparum and does not protect against dengue, caused by the dengue virus.
**Clinical Pearl:** The development of synthetic "cocktail" vaccines, like SPf66, offers an innovative approach to combat infectious diseases. These vaccines can target multiple antigens from a single organism, enhancing immune response and potentially improving protection against the targeted pathogen. In the case of SPf66, it demonstrates the potential of synthetic vaccines to combat malaria, a major global health concern.